Skip to content

Radiologic Examination

PROCEDURE9 trials

Sponsors

National Cancer Institute (NCI), KU Leuven, Istanbul University, Children's Oncology Group

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced LymphomaAdvanced Malignant Solid NeoplasmAppendicitis AcuteBladder CarcinomaBoxer's FractureBreast Carcinoma

Phase 1

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Active, not recruitingNCT02465060
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49
Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-04-03
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
Active, not recruitingNCT06136897
National Cancer Institute (NCI)Malignant Solid Neoplasm
Start: 2017-03-23End: 2027-01-15Updated: 2026-04-03
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
Active, not recruitingNCT06303167
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3
Start: 2016-01-08End: 2027-01-15Updated: 2026-04-03
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
Active, not recruitingNCT06357975
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma +2
Start: 2016-07-29End: 2026-12-31Updated: 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
Active, not recruitingNCT06360588
National Cancer Institute (NCI)Malignant Solid Neoplasm
Start: 2018-10-08End: 2027-01-15Updated: 2026-04-03
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
Active, not recruitingNCT06360575
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma +2
Start: 2016-07-20End: 2026-12-31Updated: 2026-03-20

Unknown Phase

Related Papers

Journal of Clinical Oncology2023-06-011 citations

17 more papers not shown